使用SOMAscan蛋白质组学平台的非靶向分析结果表明循环蛋白与糖尿病进展至肾衰竭风险的新关联
该研究纳入四个独立队列共754例1型和2型糖尿病伴早期和晚期糖尿病肾病患者,随访十年间227例进展至肾衰竭。使用SOMAscan平台检测基线1129种循环蛋白,对其中795种进行非靶向分析,发现11种蛋白与进展至肾衰竭显著相关,LASSO回归显示5种蛋白独立相关。
要点
- 在795种非靶向分析的循环蛋白中,11种与糖尿病进展至肾衰竭显著相关。
- LASSO回归显示LAYN、ESAM、DLL1、MAPK11和endostatin五种蛋白独立关联进展风险。
- DLL1、ESAM和MAPK11在全部SOMAscan结果中被选为候选生物标志物。
核心结论
- 本研究识别出的蛋白可能被视为预测糖尿病肾病进展至肾衰竭风险的新候选预后生物标志物。
- 这些蛋白参与糖尿病肾病进展的具体机制必须进一步研究,以评估其作为肾脏保护治疗靶点的价值。
研究设计与样本
- 研究纳入四个独立队列,共754例1型和2型糖尿病伴早期和晚期糖尿病肾病患者,随访十年以确定进展至肾衰竭。
- 使用SOMAscan蛋白质组学平台检测基线1129种循环蛋白浓度,对其中795种进行非靶向分析。
主要发现
- 十年随访期间,754例中227例进展至肾衰竭。
- 在795种剩余蛋白中,11种与进展至肾衰竭显著相关。
- 这些蛋白此前报道的生物学过程涉及神经元发育(DLL1、MATN2、NRX1B、KLK8、RTN4R和ROR1),并在细胞和动物研究中与肾脏纤维化发展相关(LAYN、DLL1、MAPK11、MATN2、endostatin和ROR1)。
- 使用多变量LASSO回归分析,五种蛋白(LAYN、ESAM、DLL1、MAPK11和endostatin)被发现在进展至肾衰竭风险中独立相关。
临床怎么用
- 原文未据此给出推荐。
局限性
- 这些蛋白参与糖尿病肾病进展的具体机制必须进一步研究,以评估其作为肾脏保护治疗靶点的价值。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
This study applies a large proteomics panel to search for new circulating biomarkers associated with progression to kidney failure in individuals with diabetic kidney disease. Four independent cohorts encompassing 754 individuals with type 1 and type 2 diabetes and early and late diabetic kidney disease were followed to ascertain progression to kidney failure. During ten years of follow-up, 227 of 754 individuals progressed to kidney failure. Using the SOMAscan proteomics platform, we measured baseline concentration of 1129 circulating proteins. In our previous publications, we analyzed 334 of these proteins that were members of specific candidate pathways involved in diabetic kidney disease and found 35 proteins strongly associated with risk of progression to kidney failure. Here, we examined the remaining 795 proteins using an untargeted approach. Of these remaining proteins, 11 were significantly associated with progression to kidney failure. Biological processes previously reported for these proteins were related to neuron development (DLL1, MATN2, NRX1B, KLK8, RTN4R and ROR1) and were implicated in the development of kidney fibrosis (LAYN, DLL1, MAPK11, MATN2, endostatin, and ROR1) in cellular and animal studies. Specific mechanisms that underlie involvement of these proteins in progression of diabetic kidney disease must be further investigated to assess their value as targets for kidney-protective therapies. Using multivariable LASSO regression analysis, five proteins (LAYN, ESAM, DLL1, MAPK11 and endostatin) were found independently associated with risk of progression to kidney failure. Thus, our study identified proteins that may be considered as new candidate prognostic biomarkers to predict risk of progression to kidney failure in diabetic kidney disease. Furthermore, three of these proteins (DLL1, ESAM, and MAPK11) were selected as candidate biomarkers when all SOMAscan results were evaluated.
引用
- Kobayashi H, Looker HC, Satake E, et al. Results of untargeted analysis using the SOMAscan proteomics platform indicates novel associations of circulating proteins with risk of progression to kidney failure in diabetes. Kidney Int. 2022. PMID: 35618095. doi:10.1016/j.kint.2022.04.022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。